PWH (all) | PWH without clinical significant fibrosis (Stiffness < 7.1 kPa) | PWH with clinical significant fibrosis (Stiffness ≥ 7.1) | P-value | |
---|---|---|---|---|
Total number of participants n (%) | 141 (100) | 116 (82.3) | 25 (17.7) | N.a |
Age (years) | 47 (24–72) | 46 (24–72) | 52 (36–67) | 0.004 |
Sex (male/female) | 120/21 | 100/20 | 20/1 | N.s |
BMI (kg/cm2) | 24 (19–36) | 24 (20–36) | 24 (19–32) | N.s |
AST (U/L) | 23 (9–93) | 22 (9–65) | 27 (11–93) | 0.037 |
ALT (U/L) | 29 (10–110) | 29 (10–103) | 33 (10–110) | N.s |
GGT (U/L) | 46 (16–302) | 45 (16–302) | 60 (26–248) | N.s |
Thrombocytes | 206 (46–400) | 213 (123–400) | 167 (46–259) | 0.0001 |
Transient elastography (kPa) | 4.9 (2.0–49.6) | 4.6 (2.0–6.9) | 9.3 (7.1–49.6) | N.a |
Steatosis CAP (dB/m) | 232 (100–378) | 231 (100–378) | 236 (101–364) | N.s |
Cholinesterase | 13,264 (7168–24,175) | 13,797 (7168–22,233) | 11,028 (7567–24,175) | N.s |
PC3X (ng/ml) | 6.7 (1.5–33.3) | 6.5 (1.5–33.3) | 7.5 (4.6–30.1) | 0.0078 |
PRO-C5 (ng/ml) | 465.0 (130.0–998.4) | 463 (130.0–828.5) | 476.6 (130.0–998.4) | N.s |
PRO-C6 (ng/ml) | 6.9 (3.7–22.6) | 6.8 (3.7–22.6) | 7.9 (5.3–18.5) | 0.0003 |
Anti-HCV-positive (%) | 18 (12.8) | 11 (9.5) | 7 (28.0) | N.s |
Hbs-Ag positive (%) | 4 (2.8) | 3 (2.6) | 1 (4.0) | N.s |